Skip to main content
Daily Report

Daily Sepsis Research Analysis

05/08/2026
3 papers selected
32 analyzed

Analyzed 32 papers and selected 3 impactful papers.

Summary

Three studies advance sepsis science across mechanism and translation: (1) epithelial FGF20 restores alveolar barrier integrity and restrains intrapulmonary coagulation via FGFR1–PI3K–AKT signaling, improving survival in preclinical sepsis-induced lung injury with supportive human ARDS correlations; (2) IFI27 impairs Treg IL-10/STAT3 signaling, amplifying ferroptosis and lung damage, linking a measurable biomarker to a targetable pathway; (3) single-cell multi-cohort analyses identify cDC1-centered ubiquitination dysregulation and highlight UBE2F as a diagnostic and therapeutic candidate.

Research Themes

  • Epithelial-immune crosstalk controlling barrier integrity and coagulation in sepsis-induced lung injury
  • Immune endotyping and regulatory pathways (IFI27–Treg–IL-10/STAT3; ferroptosis) in sepsis
  • Ubiquitination dysregulation in dendritic cells and identification of UBE2F as a translational target

Selected Articles

1. FGF20 activates FGFR1-PI3K-AKT signaling to coordinate barrier integrity and alveolar coagulation in sepsis-induced lung injury.

76Level IVBasic/Mechanistic (translational preclinical)
Cellular signalling · 2026PMID: 42097317

In CLP-induced sepsis lung injury, recombinant FGF20 improved 7-day survival, reduced edema/inflammation, and stabilized the alveolar-capillary barrier while suppressing TF/PAI-1 via FGFR1–PI3K–AKT. Human ARDS samples showed reduced FGF20 correlating with worse oxygenation, positioning FGF20 as a mechanistically anchored therapeutic target that integrates barrier preservation and immunothrombotic restraint.

Impact: This work reveals an epithelial-derived checkpoint that simultaneously stabilizes barrier architecture and curbs procoagulant signaling, with both survival benefit in vivo and clinical correlations. It nominates FGF20 as a tractable, pathway-defined target for sepsis-induced ALI/ARDS.

Clinical Implications: FGF20 measurement could inform ARDS risk stratification, and FGF20 agonism or replacement warrants early-phase trials as a complement to lung-protective care, potentially reducing immunothrombotic injury without broad immunosuppression.

Key Findings

  • Recombinant human FGF20 improved 7-day survival and reduced edema/inflammation in CLP rat sepsis-induced lung injury.
  • FGF20 via FGFR1–PI3K–AKT suppressed NF-κB activation, downregulated TF and PAI-1, and stabilized E-/VE-cadherin and ZO-1 through GSK3β Ser9 phosphorylation.
  • FGFR1 or AKT inhibition abrogated both barrier-protective and anticoagulant effects, confirming pathway dependency.
  • FGF20 levels were reduced in ARDS patients and positively correlated with PaO2/FiO2, linking deficiency to severity.

Methodological Strengths

  • Prophylactic and therapeutic testing in a standardized CLP rat model with survival endpoints
  • Mechanistic validation using pathway inhibitors and junctional protein assays, plus human ARDS biomarker correlation

Limitations

  • Preclinical animal study; human interventional data absent
  • Dosing, timing, and off-target safety profiles of rhFGF20 require clinical evaluation

Future Directions: Conduct phase 1/2 trials of FGF20 (or FGFR1–AKT axis modulation) with biomarker-guided enrollment; assess synergy with anticoagulation and lung-protective ventilation; evaluate long-term fibrosis and thromboinflammation endpoints.

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are pathologically characterized by disruption of the alveolar-capillary barrier, excessive inflammatory responses, and dysregulated intra-pulmonary coagulation. Although inflammatory and thrombotic cascades have been extensively studied, endogenous epithelial-derived signaling mechanisms coordinating barrier stabilization with immunothrombotic restraint remain undefined. Here, we identify fibroblast growth factor 20 (FGF20) as a constitutive epithelial regulator suppressed in alveolar barrier-associated cells during sepsis-induced ALI. In a CLP rat model, both prophylactic and therapeutic administration of recombinant human FGF20 (rhFGF20) improved 7-day survival, attenuated pulmonary edema and inflammation, restored gas exchange, and preserved alveolar-capillary integrity. rhFGF20 restrained procoagulant and antifibrinolytic mediators tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) while suppressing NF-κB activation. Mechanistically, FGF20 acted through fibroblast growth factor receptor 1 (FGFR1) to engage the FGFR1-PI3K-AKT cascade. AKT activation bifurcated into two axes: (i) inhibition of NF-κB phosphorylation and nuclear translocation, restraining TF/PAI-1 transcription; and (ii) inhibitory phosphorylation of glycogen synthase kinase 3β (GSK3β) at Ser9, stabilizing epithelial and endothelial junctional proteins (E-cadherin, VE-cadherin, ZO-1). Pharmacological inhibition of FGFR1 or AKT abolished both barrier-protective and anticoagulant effects, confirming pathway dependency. Clinically, serum and bronchoalveolar lavage fluid FGF20 levels were reduced in ARDS patients and positively correlated with PaO₂/FiO₂ ratios, linking reduced FGF20 to disease severity. Collectively, these findings position FGF20 as an upstream integrator of structural and immunothrombotic homeostasis within the alveolar-capillary unit. Restoration of the FGF20-FGFR1 axis reconstitutes a proximal checkpoint stabilizing barrier architecture and constraining NF-κB-dependent procoagulant activation, highlighting FGF20 as a mechanistically grounded therapeutic target in sepsis-induced ALI/ARDS. CLINICAL SIGNIFICANCE.

2. IFI27-mediated regulation of regulatory T cells aggravates lung injury in sepsis via IL-10/STAT3 signaling.

73Level IVBasic/Mechanistic (translational)
Frontiers in immunology · 2026PMID: 42099627

Plasma IFI27 levels correlate with sepsis severity and mechanistically impair Treg function by inhibiting STAT5 and IL-10/STAT3 signaling, increasing lipid peroxidation and ferroptosis in lung epithelium. IFI27 thus links a measurable biomarker with a targetable immunoregulatory and ferroptotic pathway in sepsis-associated lung injury.

Impact: The study integrates clinical biomarker data with mechanistic insights, positioning IFI27 as both a prognostic indicator and a gateway to Treg- and ferroptosis-targeted interventions in sepsis lung injury.

Clinical Implications: Monitoring IFI27 could aid risk stratification. Therapeutically, restoring IL-10/STAT3 signaling or directly modulating IFI27/Treg pathways and ferroptosis may mitigate sepsis-induced lung injury.

Key Findings

  • Plasma IFI27 positively correlates with clinical sepsis severity and is elevated in septic mice.
  • IFI27 inhibits STAT5 phosphorylation, reducing Treg abundance and IL-10 secretion.
  • Reduced IL-10/STAT3 signaling and increased lipid peroxidation enhance ferroptosis in lung epithelial cells, aggravating lung injury.

Methodological Strengths

  • Combined human biomarker analysis with mechanistic pathway interrogation in animal models
  • Clear linkage between signaling alterations (STAT5, IL-10/STAT3) and cellular fate (ferroptosis)

Limitations

  • Causality in humans remains to be demonstrated; interventional human data are lacking
  • Sample sizes and external validation cohorts are not detailed, limiting generalizability

Future Directions: Prospective validation of IFI27 as a prognostic biomarker; interventional studies targeting IFI27/Treg axes or ferroptosis; exploration of combinatorial immunomodulation in sepsis-associated lung injury.

BACKGROUND AND PURPOSE: Interferon-induced protein 27 (IFI27) is implicated in immune regulation, and regulatory T cells (Tregs) play a critical role in maintaining pulmonary immune homeostasis during sepsis. However, the relationship between IFI27 and Treg-mediated regulation in sepsis-associated lung injury remains unclear. This study aimed to investigate the role of IFI27 in modulating Treg function during sepsis. METHODS: Plasma IFI27 levels were measured in patients with sepsis and healthy controls. mRNA sequencing was performed to assess IFI27 expression profiles. RESULTS: Clinical analyses demonstrated that plasma IFI27 levels were positively correlated with sepsis severity. IFI27 expression was significantly increased in septic mice. Elevated IFI27 inhibited STAT5 phosphorylation, leading to a reduction in Treg abundance and IL-10 secretion, thereby exacerbating ferroptosis in pulmonary epithelial cells. Furthermore, IFI27 elevation in Tregs increased lipid peroxidation levels by suppressing the IL-10/STAT3 signaling pathway. CONCLUSIONS: These findings indicate that IFI27 is closely associated with sepsis severity and may serve as a potential prognostic indicator. Mechanistically, IFI27 suppresses Treg function and enhances ferroptosis in lung epithelial cells through inhibition of the IL-10/STAT3 signaling pathway, thereby aggravating sepsis-induced lung injury.

3. Integrated single-cell and bulk transcriptomic analyses reveal cDC1-centered ubiquitination dysregulation and identify UBE2F as a critical regulator in sepsis.

71.5Level VBasic/Mechanistic (multi-omics discovery)
Frontiers in immunology · 2026PMID: 42099630

Across multi-cohort single-cell and bulk datasets, cDC1 emerges as the immune hub of ubiquitination dysregulation in human sepsis, with TNF–TNFRSF1B signaling central to crosstalk. Four ubiquitination genes show reproducible diagnostic value, and UBE2F stands out with strongest upregulation and functional relevance in LPS-stimulated dendritic cells.

Impact: This study pinpoints a specific immune subset (cDC1) and a ubiquitination enzyme (UBE2F) as convergent nodes for diagnosis and intervention, grounded in robust multi-algorithm integration and cross-cohort reproducibility with functional support.

Clinical Implications: UBE2F and related ubiquitination signatures could enable early immune endotyping and risk stratification in sepsis, and motivate development of ubiquitination-targeted therapeutics or diagnostics.

Key Findings

  • cDC1 displayed the most pronounced ubiquitination-related transcriptional activation among immune subsets in sepsis.
  • TNF–TNFRSF1B emerged as a key cDC1-mediated communication axis specific to sepsis.
  • Four ubiquitination genes (CUL1, UBE2F, UBE2N, UBE3A) showed reproducible diagnostic performance across independent cohorts, with UBE2F strongest and functionally supported in LPS-stimulated DCs.

Methodological Strengths

  • Large-scale integration of 315,220 single cells with independent bulk cohorts and multi-algorithm feature selection
  • Functional validation in LPS-stimulated dendritic cells supports computational discoveries

Limitations

  • Primarily omics-based and cross-sectional; lacks in vivo validation demonstrating causality
  • Clinical utility thresholds and prospective diagnostic performance are not established

Future Directions: Prospective validation of UBE2F-based diagnostics and cDC1-focused endotyping; mechanistic in vivo studies to test causality and therapeutic modulation of ubiquitination in sepsis.

BACKGROUND: Sepsis is a life-threatening syndrome with dysregulated immune responses and multiple organ dysfunction. However, precise diagnostic biomarkers and effective therapeutic targets for this syndrome are still lacking. Protein ubiquitination modulates inflammatory regulation and immune cell function, but the specific immune cell subsets that drive ubiquitination-associated immune dysregulation in human sepsis have not been clearly identified. METHODS: An integrated analysis was performed using 315,220 single cells from two single-cell RNA sequencing (scRNA-seq) datasets in conjunction with independent bulk transcriptomic cohorts. We quantified cell-type responsiveness using Augur, inferred intercellular communication via CellChat, and identified ubiquitination-related gene networks through weighted gene co-expression network analysis (WGCNA) and subsequent multi-algorithm feature selection. Functional validation was conducted with lipopolysaccharide (LPS)-stimulated murine dendritic cells (DCs) line - DC2.4 RESULTS: conventional Dendritic cells (cDCs) were identified as the most transcriptionally perturbed immune population in sepsis, with subsequent subclustering revealing that the type-1 conventional dendritic cells (cDC1) subset specifically exhibited pronounced activation of ubiquitination signatures. Cell-cell communication analysis identified TNF signaling as a sepsis-specific pathway, in which cDC1 functions as a critical mediator predominantly via the TNF-TNFRSF1B axis. Four ubiquitination-related genes (CUL1, UBE2F, UBE2N and UBE3A) demonstrated reproducible diagnostic performance across three independent cohorts. Notably, UBE2F showed the strongest upregulation and functional relevance in sepsis models. Both CONCLUSIONS: Our results reveal cDC1 as a key immune cell subset involved in ubiquitination-mediated immune dysregulation in sepsis and suggests that UBE2F may serve as a potential diagnostic biomarker and therapeutic target.